Titular:
Schering-Plough cut at Merrill, Vytorin/Zetia concerns cited
Flash:
LONDON (MarketWatch) -- Merrill Lynch cut its rating on Schering-Plough to underperform from neutral and lowered its price target to $18 from $22, saying it expects the efficacy and safety controversies around Vytorin/Zetia to continue. In addition, the broker told clients that the drugmaker has the greatest currency risk of U.S. peers.